Celgene Corp CELG:NASDAQ

Last Price$97.31Cboe Real-Time Last Sale as of 12:32PM ET 6/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.80(0.83%)
Bid (Size)$97.31 (400)
Ask (Size)$97.32 (100)
Day Low / High$96.36 - 97.54
Volume1.4 M
 

View Biotechnology IndustryPeer Comparison as of 06/17/2019

 

Celgene Corp ( NASDAQ )

Price: $97.31
Change: +0.80 (0.83%)
Volume: 1.4 M
12:32PM ET 6/17/2019
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Gilead Sciences Inc ( NASDAQ )

Price: $67.23
Change: +0.87 (1.31%)
Volume: 1.9 M
12:32PM ET 6/17/2019
 
 

Illumina Inc ( NASDAQ )

Price: $348.63
Change: +4.63 (1.35%)
Volume: 320.3 K
12:32PM ET 6/17/2019
 
 

Biogen Inc ( NASDAQ )

Price: $232.46
Change: +4.79 (2.10%)
Volume: 805.1 K
12:32PM ET 6/17/2019
 

Read more news Recent News

BeiGene Ends Global Collaboration on Tislelizumab with Celgene Ahead of Bristol-Myers Squibb Merger
9:00AM ET 6/17/2019 MT Newswires

BeiGene (BGNE) said Monday it has agreed to terminate its collaboration with Celgene Corporation (CELG) on tislelizumab, BeiGene's investigational...

Celgene Decides Not to License Mereo Biopharma's Etigilimab Cancer Drug
9:10AM ET 6/13/2019 MT Newswires

Mereo Biopharma (MREO) said pre-market Thursday that Celgene (CELG) has notified the company's subsidiary, OncoMed Pharmaceuticals, that it will not...

Celgene Applications for MS Drug Ozanimod Accepted by FDA and EMA
8:06AM ET 6/06/2019 MT Newswires

Celgene (CELG) said the US Food and Drug Administration and European Medicines Agency have accepted its new drug application and marketing authorization...

Insider Trends: Insider at Celgene Converts Options in Mist of 90-Day Buying Trend
4:07PM ET 6/05/2019 MT Newswires

Michael D Casey, Director, exercised options for 24,666 shares in Celgene (CELG) for $554,245 on Jun 03, 2019. Casey, following the transactions...

View all Commentary and Analysis

An In-Depth Look At Jounce Therapeutics
11:24AM ET 6/17/2019 Seeking Alpha

Regeneron (REGN) Presents Positive Data on Lymphoma Candidate
8:12AM ET 6/17/2019 Zacks

Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or...

Celgene's Long Journey Through Regulatory Filings For Ozanimod Might Finally Pay Off
11:58AM ET 6/12/2019 Seeking Alpha

How To Find Undervalued Stocks In The Healthcare Sector
4:10PM ET 6/10/2019 Seeking Alpha

Company Profile

Business DescriptionCelgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include REVLIMID, POMALYST, IMNOVID, OTEZLA, ABRAXANE, and VIDAZA. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. View company web site for more details
Address86 Morris Avenue
Summit, New Jersey 07901
Phone+1.908.673.9000
Number of Employees8,852
Recent SEC Filing06/05/20194
Chairman, President, CEO & COOMark J. Alles
CFO, Principal Accounting Officer & Executive VPDavid V. Elkins
Chief Medical OfficerJay T. Backstrom
Chief Digital & Information Officer, Senior VPAijaz Tobaccowalla

Company Highlights

Price Open$96.34
Previous Close$96.51
52 Week Range$58.59 - 97.54
Market Capitalization$68.6 B
Shares Outstanding705.3 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement07/25/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings14.69
Earnings per Share$7.17
Beta vs. S&P 500N/A
Revenue$15.3 B
Net Profit Margin30.17%
Return on Equity83.92%

Analyst Ratings as of 06/07/2019

Buy
1
Overweight
2
Hold
17
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset